Search the database for deliberate release of GM medicinal products
Displaying 1 - 2 of 2
|EU record number
|Company / Sponsor
|Only notified under the "contained use" procedure. Dossier submitted on 26/03/1998.
|Pilot study of immunization with recombinant canarypox virus vCP1469A expressing the MAGE-1.A1 and MAGE-3.A1 cytolytic T lymphocytes epitopes in patients with malignant melanoma, non-small cell lung carcinoma, head-and-neck squamous cell carcinoma, esopha
|Pasteur Mérieux Connaught
|HLA-A1 restricted CTL epitope of MAGE-1 and MAGE-3 genes
|Only notified under the "contained use" procedure. Dossier submitted on 24/10/1996.
|Prospective, open-label, parallel-group, randomized, multicenter trial comparing the efficacy of surgery, radiation, and injection of murine cells producing herpes simplex thymidine kinase vector followed by intravenous ganciclovir against the efficacy of
|Genetic therapy, Inc., Sandoz Pharma, Ltd
|Thymidine Kinase (HSV-TK1), neomycin resistance (NeoR)